7 results about "Endothelial Cell Growth Factor" patented technology

The invention provides a functional beverage and an application thereof in anti-hypoxia. The functional beverage disclosed by the invention is obtained by compounding a lonicera caerulea extracting solution, an acanthopanax extracting solution and a schisandra chinensis extracting solution according to a specific ratio. The functional beverage can prolong the survival time of an organism in a closed hypoxia environment, relieve lung edema or hyperemia symptoms caused by hypoxia, relieve lung pathological changes caused by hypoxia, effectively reduce the levels of protein kinase B alpha, vascular endothelial cell growth factors and hypoxia-inducible factor-1 alpha in lungs, and improve the immunity of the lungs. Therefore, oxidative stress injury can be inhibited, the anti-hypoxia capability of an organism is improved, and a good anti-hypoxia effect is achieved. In addition, the functional beverage also has good biological safety, easily acceptable flavor and stable state, and is suitable for industrial popularization.

This invention relates to the field of biomedical materials technology, providing a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold material, its preparation method, and its applications. The preparation method includes: decellularizing adipose tissue to obtain adipose tissue decellularized scaffold; heparinizing the scaffold to obtain a heparinized adipose tissue decellularized scaffold; loading hepatocyte growth factor and vascular endothelial cell growth factor onto the scaffold to obtain a heparinized dual-growth factor adipose tissue decellularized scaffold; seeding induced pluripotent stem cell-derived hepatocytes onto the scaffold, and culturing to obtain a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold (RAT). This invention uses rat inguinal adipose tissue to prepare RAT material, which is low-cost, readily available, has a simple preparation process, and is easy to scale up. The RAT material of this invention can achieve liver tissue damage repair and hepatocyte regeneration, providing a new treatment strategy for acute liver failure.

The present application relates to the application of phospholipids in regulating angiogenesis, and the present application applies various phospholipids and products thereof to a zebrafish model to evaluate the influence of the phospholipids on the damage of intersegmental vessels (ISVs) induced by vascular endothelial cell growth factor receptor inhibitor (PTK787) and the growth of subintestinal vessels (SIVs) in the zebrafish, and it is found for the first time that phospholipids from different sources and in different forms can reverse the damage of ISVs induced by PTK787, significantly promote the growth of SIVs in the zebrafish, and increase the length of the generated blood vessels to different degrees, and have small toxic and side effects; the present application can provide candidates for preparing drugs for vascular diseases, and has a good application prospect.

The application discloses a compound with a general formula (I), a pharmaceutically acceptable salt, a hydrate or a prodrug of the compound, and application of the compound in preparation of a medicine for preventing and / or treating diseases mediated by tyrosine kinase and / or histone deacetylase. The compound can simultaneously produce a good inhibiting effect on multiple targets (especially histone deacetylase 1, histone deacetylase 6 and two tyrosine kinases (vascular endothelial cell growth factor receptor and platelet-derived growth factor receptor)), and is expected to be used in treatment of malignant tumors.

The present application relates to a kind of targeting immunoregulation and anti-tumor morchella bifunctional glycopeptide, belong to the field of biotechnology.The molecular sequence of morchella glycopeptide provided by the present application is LPS (Fuc) PMLLPQ, and the fucose of morchella glycopeptide molecule is connected to the serine hydroxyl of peptide chain by O-connection glycosylation mode with α-glycosidic bond.The morchella glycopeptide of the present application is obtained from the morchella extract extracted by pectinase with morchella as substrate, is derived from edible fungi, and is safe to use;Can effectively bind TLR4 (Toll-like receptor 4), block inflammatory response, effectively bind and inhibit VEGFR2 (vascular endothelial cell growth factor receptor-2), and has antitumor activity;It can also inhibit the release of macrophage cytokines induced by LPS, further indicating that the morchella glycopeptide of the present application has immunoregulatory and antitumor activity.

Aspects of the disclosure relate to recombinant adenoviruses (e.g., rAAV2.7m8-KH902) encoding anti-vascular endothelial cell growth factor (VEGF) agents in a cell or subject. In some embodiments, the compositions described herein can be used to treat a subject having a disease associated with angiogenesis or aberrant VEGF activity / signaling.

The application discloses a serum-free culture medium for vascular endothelial cells and application thereof, and belongs to the technical field of cell culture. The serum-free culture medium for vascular endothelial cells comprises a basic culture medium, and further comprises human serum albumin, endothelial cell growth factor, epidermal growth factor, follicular inhibin-like recombinant protein 1, fibroblast growth factor, insulin-like growth factor, heparin sodium, hydrocortisone, L-glutamine and ascorbic acid. The serum-free culture medium has the advantages of clear components, stable quality and low cost, can promote the division and proliferation of vascular endothelial cells, can better maintain the state of endothelial cells, has high scientific research and medical application values, and can make the cultured vascular endothelial cells have the advantages of high proliferation speed, short doubling time, good cell state, high survival rate and high activity. In addition, the serum-free culture medium does not contain xenoantigen components, will not cause an immune rejection reaction with the human body, and is suitable for industrialized production of vascular endothelial cell related products.